Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
US FDA grants priority voucher to J&J's blood cancer treatment
10:39am, Monday, 15'th Dec 2025
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products recei
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
10:31am, Monday, 15'th Dec 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
10:11am, Monday, 15'th Dec 2025
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
Hilltop Partners LLC Raises Stock Holdings in Johnson & Johnson $JNJ
05:34am, Monday, 15'th Dec 2025
Hilltop Partners LLC increased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchan
Geneos Wealth Management Inc. Lowers Stake in Johnson & Johnson $JNJ
04:09am, Monday, 15'th Dec 2025
Geneos Wealth Management Inc. cut its position in shares of Johnson and Johnson (NYSE: JNJ) by 12.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Forget the 2.8% Social Security Increase. These Aristocrats Pay You 4% to 7% More Annually
09:51am, Sunday, 14'th Dec 2025
The Social Security Administration announced in October that beneficiaries will receive a 2.8% cost-of-living adjustment (COLA) in 2026, following a 2.5% increase in 2025.
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson
09:00am, Sunday, 14'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after dec
5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
12:26pm, Saturday, 13'th Dec 2025
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable busin
AQR Capital Management LLC Has $728.72 Million Stock Holdings in Johnson & Johnson $JNJ
08:16am, Saturday, 13'th Dec 2025
AQR Capital Management LLC trimmed its position in Johnson and Johnson (NYSE: JNJ) by 8.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Ameriprise Financial Inc. Cuts Stock Holdings in Johnson & Johnson $JNJ
03:58am, Saturday, 13'th Dec 2025
Ameriprise Financial Inc. cut its position in shares of Johnson and Johnson (NYSE: JNJ) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson
09:57pm, Friday, 12'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury today delivered a $40 million verdict against Johnson & Johnson. The trial featured two California women who developed ovarian cancer af
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial
09:08pm, Friday, 12'th Dec 2025
A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mu
These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?
12:30pm, Friday, 12'th Dec 2025
A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
07:05pm, Thursday, 11'th Dec 2025
Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is p
